Thromb Haemost 2001; 86(06): 1379-1384
DOI: 10.1055/s-0037-1616739
Review Article
Schattauer GmbH

Low Molecular Weight Heparin and Warfarin in the Treatment of Patients with Antiphospholipid Syndrome during Pregnancy

Rachel Pauzner
Sheba Medical Center, Sackler School of Medicine and School of Engineering, Tel-Aviv University, Israel
,
Mordechai Dulitzki
Sheba Medical Center, Sackler School of Medicine and School of Engineering, Tel-Aviv University, Israel
,
Pnina Langevitz
Sheba Medical Center, Sackler School of Medicine and School of Engineering, Tel-Aviv University, Israel
,
Avi Livneh
Sheba Medical Center, Sackler School of Medicine and School of Engineering, Tel-Aviv University, Israel
,
Ron Kenett
Sheba Medical Center, Sackler School of Medicine and School of Engineering, Tel-Aviv University, Israel
,
Amira Many
Sheba Medical Center, Sackler School of Medicine and School of Engineering, Tel-Aviv University, Israel
› Author Affiliations
Further Information

Publication History

Received 10 February 2001

Accepted after resubmission 06 August 2001

Publication Date:
12 December 2017 (online)

Preview

Summary

Fifty-seven pregnancies in women with antiphospholipid syndrome (APS) are presented. These were treated with s.c. enoxaparin and low dose aspirin. In fourteen pregnancies warfarin was prescribed between weeks 15-34 (warfarin group). The decision to switch to warfarin depended on a morbidity score, and the patient’s consent. Neither teratogenicity nor significant maternal, fetal or neonatal hemorrhage was observed. Despite the higher pretreatment morbidity score of the warfarin group, the live birth rate was high in both groups: 86% in the warfarin group and 87% in the non-warfarin group. There was no significant difference in week of delivery, birth weight, or incidence of thrombosis between the groups. The study demonstrates the efficacy and safety of anticoagulants during pregnancy. The use of LMWH in pregnant women with APS not being moot, warfarin might be justified in selected patients.